Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICCC NASDAQ:LFCR NASDAQ:NVCT NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICCCImmuCell$6.82+3.0%$6.35$3.34▼$7.60$61.65M0.3225,467 shs59,383 shsLFCRLifecore Biomedical$7.46-0.4%$7.29$3.68▼$8.85$276.24M0.71228,833 shs137,391 shsNVCTNuvectis Pharma$7.98+2.3%$8.61$4.44▼$11.80$166.70M-0.25134,563 shs64,383 shsOCGNOcugen$1.01-1.0%$0.97$0.52▼$1.72$294.95M4.184.55 million shs3.24 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICCCImmuCell0.00%+2.16%-12.89%+23.05%+59.13%LFCRLifecore Biomedical0.00%-9.76%+7.93%+24.01%+54.43%NVCTNuvectis Pharma0.00%-1.02%-4.06%-6.47%+16.07%OCGNOcugen0.00%-10.53%-3.77%+50.64%-38.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICCCImmuCell0.1849 of 5 stars0.03.00.00.01.50.00.0LFCRLifecore Biomedical0.9845 of 5 stars1.31.00.00.01.84.20.6NVCTNuvectis Pharma2.5 of 5 stars3.50.00.00.01.15.00.6OCGNOcugen1.2312 of 5 stars3.51.00.00.01.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICCCImmuCell 0.00N/AN/AN/ALFCRLifecore Biomedical 2.50Moderate Buy$8.007.24% UpsideNVCTNuvectis Pharma 3.00Buy$17.00113.03% UpsideOCGNOcugen 3.00Buy$6.00494.06% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, NVCT, OCGN, and LFCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.005/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/12/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.005/12/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICCCImmuCell$26.49M2.33$0.07 per share102.96$3.09 per share2.21LFCRLifecore Biomedical$128.26M2.15N/AN/A$0.37 per share20.16NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/AOCGNOcugen$4.05M72.83N/AN/A$0.10 per share10.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICCCImmuCell-$2.16M-$0.07N/A∞N/A-1.00%-1.02%-0.61%8/12/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-35.90%-551.09%-13.89%8/15/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)OCGNOcugen-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/1/2025 (Estimated)Latest ICCC, NVCT, OCGN, and LFCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q4 2025LFCRLifecore Biomedical-$0.0250N/AN/AN/A$35.36 millionN/A8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25N/AN/AN/AN/AN/A8/1/2025Q2 2025OCGNOcugen-$0.06N/AN/AN/A$0.35 millionN/A5/14/2025Q1 2025ICCCImmuCellN/A$0.16N/A$0.16N/A$8.07 million5/9/2025Q1 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05N/A$1.48 million5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICCCImmuCellN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICCCImmuCell0.304.122.21LFCRLifecore Biomedical66.362.711.59NVCTNuvectis PharmaN/A3.283.28OCGNOcugen1.742.602.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICCCImmuCell13.47%LFCRLifecore Biomedical83.36%NVCTNuvectis Pharma96.77%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipICCCImmuCell6.60%LFCRLifecore Biomedical32.20%NVCTNuvectis Pharma30.52%OCGNOcugen4.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICCCImmuCell709.04 million8.44 millionNot OptionableLFCRLifecore Biomedical69037.03 million25.10 millionOptionableNVCTNuvectis Pharma820.89 million14.52 millionNot OptionableOCGNOcugen80292.03 million279.50 millionOptionableICCC, NVCT, OCGN, and LFCR HeadlinesRecent News About These CompaniesOcugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership TeamJuly 21 at 8:23 AM | manilatimes.netMOcugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness DiseasesJuly 21 at 7:44 AM | quiverquant.comQOcugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership TeamJuly 21 at 7:30 AM | globenewswire.comOcugen Doses First Patient in Pivotal Trial for Stargardt Gene TherapyJuly 20 at 7:57 PM | msn.comOcugen Announces Q2 2025 Financial Results Call and Business UpdateJuly 18 at 4:53 PM | msn.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for ...July 18 at 9:32 AM | gurufocus.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for ...July 18 at 9:32 AM | gurufocus.comOcugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt DiseaseJuly 18 at 7:02 AM | globenewswire.comOcugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial ResultsJuly 17, 2025 | globenewswire.comOcugen (NASDAQ:OCGN) Shares Down 2.8% - Should You Sell?July 17, 2025 | marketbeat.comOcugen's (OCGN) "Buy" Rating Reaffirmed at HC WainwrightJune 24, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan CapitalJune 24, 2025 | marketbeat.comCarisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic DiseasesJune 23, 2025 | globenewswire.comOcugen: Three Potential Gene-Therapy Filings By 2028June 18, 2025 | seekingalpha.comOcugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt DiseaseJune 17, 2025 | msn.comOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate ...June 16, 2025 | gurufocus.comOcugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt DiseaseJune 16, 2025 | globenewswire.comOcugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness DiseasesJune 11, 2025 | quiverquant.comQOcugen To Present at BIO International Convention 2025June 11, 2025 | globenewswire.comOcugen signs binding term sheet for license of OCU400 modifier gene therapy for retinitis pigmentosa in KoreaJune 7, 2025 | pharmabiz.comPOcugen Secures Licensing Agreement for OCU400 in KoreaJune 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICCC, NVCT, OCGN, and LFCR Company DescriptionsImmuCell NASDAQ:ICCC$6.82 +0.20 (+3.02%) Closing price 04:00 PM EasternExtended Trading$6.79 -0.03 (-0.44%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Lifecore Biomedical NASDAQ:LFCR$7.46 -0.03 (-0.40%) Closing price 04:00 PM EasternExtended Trading$7.46 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Nuvectis Pharma NASDAQ:NVCT$7.98 +0.18 (+2.31%) Closing price 04:00 PM EasternExtended Trading$7.99 +0.01 (+0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Ocugen NASDAQ:OCGN$1.01 -0.01 (-0.98%) Closing price 04:00 PM EasternExtended Trading$1.01 +0.00 (+0.50%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analysts See Upside in These 5 Stocks That Just Raised Dividends MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Kinder Morgan: At the Hotspot of the Natural Gas Revolution Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
